Major cancer trial tests if more chemo in less time beats less chemo over more time
NCT ID NCT07466316
Summary
This study aims to find the best chemotherapy plan for patients newly diagnosed with intermediate-risk rhabdomyosarcoma, a rare cancer that mostly affects children and young adults. It will compare a shorter, more intense treatment to a longer, less intense treatment that includes extra 'maintenance' therapy. The goal is to see which approach helps patients live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.